Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle.

Ankavay M, Montpellier C, Sayed IM, Saliou JM, Wychowski C, Saas L, Duvet S, Aliouat-Denis CM, Farhat R, de Masson d'Autume V, Meuleman P, Dubuisson J, Cocquerel L.

Sci Rep. 2019 Apr 18;9(1):6243. doi: 10.1038/s41598-019-42737-2.

2.

Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication.

Farhat R, Ankavay M, Lebsir N, Gouttenoire J, Jackson CL, Wychowski C, Moradpour D, Dubuisson J, Rouillé Y, Cocquerel L.

Cell Microbiol. 2018 Jan;20(1). doi: 10.1111/cmi.12804. Epub 2017 Nov 17.

PMID:
29112323
3.

Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein.

Montpellier C, Wychowski C, Sayed IM, Meunier JC, Saliou JM, Ankavay M, Bull A, Pillez A, Abravanel F, Helle F, Brochot E, Drobecq H, Farhat R, Aliouat-Denis CM, Haddad JG, Izopet J, Meuleman P, Goffard A, Dubuisson J, Cocquerel L.

Gastroenterology. 2018 Jan;154(1):211-223.e8. doi: 10.1053/j.gastro.2017.09.020. Epub 2017 Sep 25.

PMID:
28958858
4.

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.

Vausselin T, Séron K, Lavie M, Mesalam AA, Lemasson M, Belouzard S, Fénéant L, Danneels A, Rouillé Y, Cocquerel L, Foquet L, Rosenberg AR, Wychowski C, Meuleman P, Melnyk P, Dubuisson J.

J Virol. 2016 Sep 12;90(19):8422-34. doi: 10.1128/JVI.00404-16. Print 2016 Oct 1.

5.

Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.

Sayed IM, Verhoye L, Cocquerel L, Abravanel F, Foquet L, Montpellier C, Debing Y, Farhoudi A, Wychowski C, Dubuisson J, Leroux-Roels G, Neyts J, Izopet J, Michiels T, Meuleman P.

Gut. 2017 May;66(5):920-929. doi: 10.1136/gutjnl-2015-311109. Epub 2016 Mar 22.

PMID:
27006186
6.

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.

Calland N, Sahuc ME, Belouzard S, Pène V, Bonnafous P, Mesalam AA, Deloison G, Descamps V, Sahpaz S, Wychowski C, Lambert O, Brodin P, Duverlie G, Meuleman P, Rosenberg AR, Dubuisson J, Rouillé Y, Séron K.

J Virol. 2015 Oct;89(19):10053-63. doi: 10.1128/JVI.01473-15. Epub 2015 Jul 22.

7.

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Fénéant L, Potel J, François C, Sané F, Douam F, Belouzard S, Calland N, Vausselin T, Rouillé Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L.

J Virol. 2015 Aug;89(16):8346-64. doi: 10.1128/JVI.00192-15. Epub 2015 Jun 3.

8.

Regulation of core expression during the hepatitis C virus life cycle.

Afzal MS, Alsaleh K, Farhat R, Belouzard S, Danneels A, Descamps V, Duverlie G, Wychowski C, Zaidi Nu, Dubuisson J, Rouillé Y.

J Gen Virol. 2015 Feb;96(Pt 2):311-21. doi: 10.1099/vir.0.070433-0. Epub 2014 Oct 28.

PMID:
25351725
9.

A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell-mediated immune responses in mice.

Aguilar-Noriega D, Alvarez-Lajonchere L, Brown E, Santana FL, Dubuisson J, Wychowski C, Guerra I, Martínez-Donato G, Pérez A, Amador-Cañizares Y, Dueñas-Carrera S.

Biotechnol Appl Biochem. 2014 Nov-Dec;61(6):627-36. doi: 10.1002/bab.1223. Epub 2014 May 14.

PMID:
24575938
10.

HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.

Amador-Cañizares Y, Martínez-Donato G, Alvarez-Lajonchere L, Vasallo C, Dausá M, Aguilar-Noriega D, Valenzuela C, Raíces I, Dubuisson J, Wychowski C, Cinza-Estévez Z, Castellanos M, Núñez M, Armas A, González Y, Revé I, Guerra I, Pérez Aguiar A, Dueñas-Carrera S.

World J Gastroenterol. 2014 Jan 7;20(1):148-62. doi: 10.3748/wjg.v20.i1.148.

11.

Hepatitis C virus replication and Golgi function in brefeldin a-resistant hepatoma-derived cells.

Farhat R, Goueslain L, Wychowski C, Belouzard S, Fénéant L, Jackson CL, Dubuisson J, Rouillé Y.

PLoS One. 2013 Sep 18;8(9):e74491. doi: 10.1371/journal.pone.0074491. eCollection 2013.

12.

Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.

Helle F, Brochot E, Fournier C, Descamps V, Izquierdo L, Hoffmann TW, Morel V, Herpe YE, Bengrine A, Belouzard S, Wychowski C, Dubuisson J, Francois C, Regimbeau JM, Castelain S, Duverlie G.

PLoS One. 2013 Aug 5;8(8):e70809. doi: 10.1371/journal.pone.0070809. Print 2013.

13.

Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.

Anjum S, Wahid A, Afzal MS, Albecka A, Alsaleh K, Ahmad T, Baumert TF, Wychowski C, Qadri I, Penin F, Dubuisson J.

J Infect Dis. 2013 Dec 1;208(11):1888-97. doi: 10.1093/infdis/jit376. Epub 2013 Aug 1.

PMID:
23908491
14.

The antimalarial ferroquine is an inhibitor of hepatitis C virus.

Vausselin T, Calland N, Belouzard S, Descamps V, Douam F, Helle F, François C, Lavillette D, Duverlie G, Wahid A, Fénéant L, Cocquerel L, Guérardel Y, Wychowski C, Biot C, Dubuisson J.

Hepatology. 2013 Jul;58(1):86-97. doi: 10.1002/hep.26273. Epub 2013 May 14.

PMID:
23348596
15.

Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes.

Fournier C, Helle F, Descamps V, Morel V, François C, Dedeurwaerder S, Wychowski C, Duverlie G, Castelain S.

J Gen Virol. 2013 May;94(Pt 5):996-1008. doi: 10.1099/vir.0.049676-0. Epub 2013 Jan 3.

PMID:
23288424
16.

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.

Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouillé Y, Séron K.

Hepatology. 2012 Mar;55(3):720-9. doi: 10.1002/hep.24803.

PMID:
22105803
17.

Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies.

Delavalle PY, Alsaleh K, Pillez A, Cocquerel L, Allet C, Dumont P, Loyens A, Leteurtre E, Omary MB, Dubuisson J, Rouillé Y, Wychowski C.

Exp Cell Res. 2011 Nov 1;317(18):2683-94. doi: 10.1016/j.yexcr.2011.08.018. Epub 2011 Aug 31.

PMID:
21907707
18.

Griffithsin has antiviral activity against hepatitis C virus.

Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, Wychowski C, Leroux-Roels G, Palmer KE, Dubuisson J.

Antimicrob Agents Chemother. 2011 Nov;55(11):5159-67. doi: 10.1128/AAC.00633-11. Epub 2011 Sep 6.

19.

Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry.

Maurin G, Fresquet J, Granio O, Wychowski C, Cosset FL, Lavillette D.

J Biol Chem. 2011 Jul 8;286(27):23865-76. doi: 10.1074/jbc.M110.213942. Epub 2011 May 9.

20.

Identification of basic amino acids at the N-terminal end of the core protein that are crucial for hepatitis C virus infectivity.

Alsaleh K, Delavalle PY, Pillez A, Duverlie G, Descamps V, Rouillé Y, Dubuisson J, Wychowski C.

J Virol. 2010 Dec;84(24):12515-28. doi: 10.1128/JVI.01393-10. Epub 2010 Oct 13.

21.

Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.

Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, Descamps V, Castelain S, Roingeard P, Duverlie G, Dubuisson J.

J Virol. 2010 Nov;84(22):11905-15. doi: 10.1128/JVI.01548-10. Epub 2010 Sep 15.

22.

Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM.

Gastroenterology. 2010 Mar;138(3):1112-22. doi: 10.1053/j.gastro.2009.11.053. Epub 2009 Dec 4.

23.

Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication.

Goueslain L, Alsaleh K, Horellou P, Roingeard P, Descamps V, Duverlie G, Ciczora Y, Wychowski C, Dubuisson J, Rouillé Y.

J Virol. 2010 Jan;84(2):773-87. doi: 10.1128/JVI.01190-09. Epub 2009 Nov 11.

24.

Enhanced anti-HCV activity of interferon alpha 17 subtype.

Dubois A, François C, Descamps V, Fournier C, Wychowski C, Dubuisson J, Castelain S, Duverlie G.

Virol J. 2009 Jun 3;6:70. doi: 10.1186/1743-422X-6-70.

25.

The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry.

Rocha-Perugini V, Lavie M, Delgrange D, Canton J, Pillez A, Potel J, Lecoeur C, Rubinstein E, Dubuisson J, Wychowski C, Cocquerel L.

BMC Microbiol. 2009 May 28;9:111. doi: 10.1186/1471-2180-9-111.

26.

A functional selection of viral genetic elements in cultured cells to identify hepatitis C virus RNA translation inhibitors.

Jaffrelo L, Chabas S, Reigadas S, Pflieger A, Wychowski C, Rumi J, Ventura M, Toulmé JJ, Staedel C.

Nucleic Acids Res. 2008 Sep;36(15):e95. doi: 10.1093/nar/gkn427. Epub 2008 Jul 9.

27.

Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus.

Castelain S, Schnuriger A, François C, Nguyen-Khac E, Fournier C, Schmit JL, Capron D, Dubuisson J, Wychowski C, Thibault V, Duverlie G.

J Infect Dis. 2008 Aug 1;198(3):332-5. doi: 10.1086/589777.

PMID:
18558868
28.

The CD81 partner EWI-2wint inhibits hepatitis C virus entry.

Rocha-Perugini V, Montpellier C, Delgrange D, Wychowski C, Helle F, Pillez A, Drobecq H, Le Naour F, Charrin S, Levy S, Rubinstein E, Dubuisson J, Cocquerel L.

PLoS One. 2008 Apr 2;3(4):e1866. doi: 10.1371/journal.pone.0001866.

29.

Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry.

Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand-Michel J, Tercé F, Cocquerel L, Wychowski C, Vu-Dac N, Dubuisson J.

Cell Microbiol. 2008 Mar;10(3):606-17. Epub 2007 Nov 2.

PMID:
17979982
30.

Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.

Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, Sacunha A, Larrey D, Dubuisson J, Coste J, McKeating J, Maurel P, Fournier-Wirth C.

J Virol. 2008 Jan;82(1):569-74. Epub 2007 Oct 17.

31.

Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity.

Brochot E, Duverlie G, Castelain S, Morel V, Wychowski C, Dubuisson J, François C.

Antivir Ther. 2007;12(5):805-13.

PMID:
17713164
32.

Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins.

Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouillé Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C.

J Gen Virol. 2007 Sep;88(Pt 9):2495-503.

PMID:
17698659
33.

Cell culture systems for the hepatitis C virus.

Duverlie G, Wychowski C.

World J Gastroenterol. 2007 May 7;13(17):2442-5. Review.

34.

Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs.

Chevalier C, Saulnier A, Benureau Y, Fléchet D, Delgrange D, Colbère-Garapin F, Wychowski C, Martin A.

Mol Ther. 2007 Aug;15(8):1452-62. Epub 2007 May 15.

35.

A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.

Fournier C, Duverlie G, François C, Schnuriger A, Dedeurwaerder S, Brochot E, Capron D, Wychowski C, Thibault V, Castelain S.

Virol J. 2007 Mar 30;4:35.

36.

Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.

Castelain S, Bonte D, Penin F, François C, Capron D, Dedeurwaerder S, Zawadzki P, Morel V, Wychowski C, Duverlie G.

J Med Virol. 2007 Feb;79(2):144-54.

PMID:
17177298
37.

Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system.

Lavie M, Voisset C, Vu-Dac N, Zurawski V, Duverlie G, Wychowski C, Dubuisson J.

Hepatology. 2006 Dec;44(6):1626-34.

PMID:
17133472
38.

A hepatitis C virus (HCV) NS3/4A protease-dependent strategy for the identification and purification of HCV-infected cells.

Breiman A, Vitour D, Vilasco M, Ottone C, Molina S, Pichard L, Fournier C, Delgrange D, Charneau P, Duverlie G, Wychowski C, Maurel P, Meurs EF.

J Gen Virol. 2006 Dec;87(Pt 12):3587-98.

PMID:
17098974
39.

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.

Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J.

J Biol Chem. 2006 Sep 1;281(35):25177-83. Epub 2006 Jun 29.

40.

Hepatitis C virus entry depends on clathrin-mediated endocytosis.

Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouillé Y.

J Virol. 2006 Jul;80(14):6964-72.

41.

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus.

Rouillé Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E, Belouzard S, McKeating J, Patel AH, Maertens G, Wakita T, Wychowski C, Dubuisson J.

J Virol. 2006 Mar;80(6):2832-41.

42.

Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins.

Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, Dubuisson J.

J Virol. 2005 Jul;79(13):8400-9.

43.

Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication.

Bonte D, François C, Castelain S, Wychowski C, Dubuisson J, Meurs EF, Duverlie G.

Arch Virol. 2004 Jul;149(7):1353-71. Epub 2004 Mar 17.

PMID:
15221536
44.

Characterization of the expression of the hepatitis C virus F protein.

Roussel J, Pillez A, Montpellier C, Duverlie G, Cahour A, Dubuisson J, Wychowski C.

J Gen Virol. 2003 Jul;84(Pt 7):1751-9.

PMID:
12810869
45.

Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins.

Cocquerel L, Op de Beeck A, Lambot M, Roussel J, Delgrange D, Pillez A, Wychowski C, Penin F, Dubuisson J.

EMBO J. 2002 Jun 17;21(12):2893-902.

46.

Subcellular localization and topology of the p7 polypeptide of hepatitis C virus.

Carrère-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J.

J Virol. 2002 Apr;76(8):3720-30.

47.

Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line.

Duvet S, Op De Beeck A, Cocquerel L, Wychowski C, Cacan R, Dubuisson J.

Glycobiology. 2002 Feb;12(2):95-101.

PMID:
11886842
48.

Variability of the nonstructural 5A protein of hepatitis C virus type 3a isolates and relation to interferon sensitivity.

Castelain S, Khorsi H, Roussel J, François C, Jaillon O, Capron D, Penin F, Wychowski C, Meurs E, Duverlie G; Agence Nationale de Recherche sur le SIDA AC11 Group.

J Infect Dis. 2002 Mar 1;185(5):573-83. Epub 2002 Feb 14.

PMID:
11865413
49.

Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.

Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, Muguet S, Depla E, Inchauspé G.

J Virol. 2001 Dec;75(24):12088-97.

50.

Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2.

Cocquerel L, Meunier JC, Op de Beeck A, Bonte D, Wychowski C, Dubuisson J.

J Gen Virol. 2001 Jul;82(Pt 7):1629-35.

PMID:
11413374

Supplemental Content

Loading ...
Support Center